抑制N-甲基-D-酸盐受体会改变动物在减少回报任务中的最佳决策
Seth D Foust1, Michael E Mains1, Hoda K AbouEich1
1Department of Psychology, Seattle Pacific University.
Behavioral neuroscience
|October 27, 2025
概括
像MK-801这样的N-甲基-D-酸盐 (NMDA) 受体对抗剂会影响大鼠的决策. 高剂量在一项任务中损害了行为,但在另一项任务中改善了行为,显示出复杂的认知效应和减少延迟敏感性.
科学领域:
- 神经科学是一个神经科学.
- 行为药理学行为药理学
- 认知科学 认知科学
背景情况:
- N-甲基-D-酸盐 (NMDA) 受体对抗剂正在研究用于情绪障碍治疗.
- 它们对认知的影响,特别是在时间决策方面,需要进一步研究.
- 之前的研究表明,对冲动性和延迟敏感性有不同的影响.
研究的目的:
- 研究NMDA受体对手MK-801对大鼠最佳食行为的影响.
- 澄清NMDA受体在与延迟即时奖励以获得更大的整体收益相关的决策中的作用.
- 在时间决策任务中,检查对MK-801反应的性别差异.
主要方法:
- 鼠 (雄性和雌性) 用固定和渐进的延迟杆执行了一个"减少回报"任务.
- 使用了两个条件:无重置 (延迟积累) 和重置 (在固定杆按下后的延迟重置).
- 在治疗前,老鼠接受了盐水或不同剂量的MK-801 (0.06,0.1,0.2 mg/kg).
主要成果:
- 高剂量的MK-801在无重置条件下影响了选择行为,并增加了非任务杆按压.
- 在重置条件下,高剂量的MK-801导致了更优的选择,尽管女性增加了遗漏的试验.
- 观察到的杆按压模式表明,在两种条件下,对延迟间隔的敏感性降低了.
结论:
- 在老鼠中,MK-801对最佳的食和任务响应性表现出复杂的,剂量依赖的影响.
- 行为结果受任务条件和性别的影响,表明复杂的NMDA受体作用.
- 这些发现凸显了对NMDA受体对抗剂认知效应和性别差异的进一步研究的需要.
更多相关视频
07:42An Automated T-maze Based Apparatus and Protocol for Analyzing Delay- and Effort-based Decision Making in Free Moving Rodents
Published on: August 2, 2018
14.3K
07:05Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
Published on: September 10, 2018
6.4K
相关概念视频
Feedback Inhibition
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
